FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148911877> ?p ?o ?g. }

• W2148911877 endingPage "3900" @default.
• W2148911877 startingPage "3887" @default.
• W2148911877 abstract "Abstract Purpose: Inhibition of the vascular endothelial growth factor (VEGF) axis is the basis of all currently approved antiangiogenic therapies. In preclinical models, anti-VEGF blocking antibodies have shown broad efficacy that is dependent on both tumor context and treatment duration. We aimed to characterize this activity and to evaluate the effects of discontinuation of treatment on the dynamics of tumor regrowth. Experimental Design: We evaluated the effects of anti-VEGF treatment on tumor growth and survival in 30 xenograft models and in genetic mouse models of cancer. Histologic analysis was used to evaluate the effects of treatment on tumor vasculature. We used a variety of treatment regimens to allow analysis of the effects of treatment duration and cessation on growth rate, survival, and vascular density. Results: Preclinical tumor models were characterized for their varied dependence on VEGF, thereby defining models for testing other agents that may complement or augment anti-VEGF therapy. We also found that longer exposure to anti-VEGF monoclonal antibodies delayed tumor growth and extended survival in established tumors from both cell transplants and genetic tumor models and prevented regrowth of a subset of residual tumors following cytoablative therapy. Discontinuation of anti-VEGF in established tumors resulted in regrowth at a rate slower than that in control-treated animals, with no evidence of accelerated tumor growth or rebound. However, more rapid regrowth was observed following discontinuation of certain chemotherapies. Concurrent administration of anti-VEGF seemed to normalize these accelerated growth rates. Conclusions: In diverse preclinical models, continuous VEGF suppression provides maximal benefit as a single agent, combined with chemotherapy, or as maintenance therapy once chemotherapy has been stopped. Clin Cancer Res; 16(15); 3887–900. ©2010 AACR." @default.
• W2148911877 created "2016-06-24" @default.
• W2148911877 creator A5007174910 @default.
• W2148911877 creator A5011313053 @default.
• W2148911877 creator A5013513864 @default.
• W2148911877 creator A5014772212 @default.
• W2148911877 creator A5032358498 @default.
• W2148911877 creator A5053838481 @default.
• W2148911877 creator A5054693563 @default.
• W2148911877 creator A5057362852 @default.
• W2148911877 creator A5062435069 @default.
• W2148911877 creator A5080743064 @default.
• W2148911877 creator A5082579643 @default.
• W2148911877 creator A5083202398 @default.
• W2148911877 date "2010-07-28" @default.
• W2148911877 modified "2023-10-02" @default.
• W2148911877 title "Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy" @default.
• W2148911877 cites W1574172480 @default.
• W2148911877 cites W1967600348 @default.
• W2148911877 cites W1967621966 @default.
• W2148911877 cites W1978139448 @default.
• W2148911877 cites W1981669485 @default.
• W2148911877 cites W1982402091 @default.
• W2148911877 cites W1983763042 @default.
• W2148911877 cites W1987111799 @default.
• W2148911877 cites W1988631826 @default.
• W2148911877 cites W1993016882 @default.
• W2148911877 cites W2001037898 @default.
• W2148911877 cites W2003160567 @default.
• W2148911877 cites W2008778169 @default.
• W2148911877 cites W2010325041 @default.
• W2148911877 cites W2015809080 @default.
• W2148911877 cites W2016569548 @default.
• W2148911877 cites W2032769992 @default.
• W2148911877 cites W2049185799 @default.
• W2148911877 cites W2053277232 @default.
• W2148911877 cites W2062756251 @default.
• W2148911877 cites W2067117806 @default.
• W2148911877 cites W2068910710 @default.
• W2148911877 cites W2079150475 @default.
• W2148911877 cites W2096952385 @default.
• W2148911877 cites W2101063198 @default.
• W2148911877 cites W2101144899 @default.
• W2148911877 cites W2103928688 @default.
• W2148911877 cites W2115188495 @default.
• W2148911877 cites W2118881364 @default.
• W2148911877 cites W2121243662 @default.
• W2148911877 cites W2135627690 @default.
• W2148911877 cites W2135636495 @default.
• W2148911877 cites W2138454311 @default.
• W2148911877 cites W2140088548 @default.
• W2148911877 cites W2143737148 @default.
• W2148911877 cites W2143743735 @default.
• W2148911877 cites W2144718958 @default.
• W2148911877 cites W2146107023 @default.
• W2148911877 cites W2147535764 @default.
• W2148911877 cites W2156728978 @default.
• W2148911877 cites W2157769714 @default.
• W2148911877 cites W2162352067 @default.
• W2148911877 cites W2162383970 @default.
• W2148911877 cites W2165820869 @default.
• W2148911877 doi "https://doi.org/10.1158/1078-0432.ccr-09-3100" @default.
• W2148911877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20554752" @default.
• W2148911877 hasPublicationYear "2010" @default.
• W2148911877 type Work @default.
• W2148911877 sameAs 2148911877 @default.
• W2148911877 citedByCount "121" @default.
• W2148911877 countsByYear W21489118772012 @default.
• W2148911877 countsByYear W21489118772013 @default.
• W2148911877 countsByYear W21489118772014 @default.
• W2148911877 countsByYear W21489118772015 @default.
• W2148911877 countsByYear W21489118772016 @default.
• W2148911877 countsByYear W21489118772017 @default.
• W2148911877 countsByYear W21489118772018 @default.
• W2148911877 countsByYear W21489118772019 @default.
• W2148911877 countsByYear W21489118772020 @default.
• W2148911877 countsByYear W21489118772021 @default.
• W2148911877 countsByYear W21489118772023 @default.
• W2148911877 crossrefType "journal-article" @default.
• W2148911877 hasAuthorship W2148911877A5007174910 @default.
• W2148911877 hasAuthorship W2148911877A5011313053 @default.
• W2148911877 hasAuthorship W2148911877A5013513864 @default.
• W2148911877 hasAuthorship W2148911877A5014772212 @default.
• W2148911877 hasAuthorship W2148911877A5032358498 @default.
• W2148911877 hasAuthorship W2148911877A5053838481 @default.
• W2148911877 hasAuthorship W2148911877A5054693563 @default.
• W2148911877 hasAuthorship W2148911877A5057362852 @default.
• W2148911877 hasAuthorship W2148911877A5062435069 @default.
• W2148911877 hasAuthorship W2148911877A5080743064 @default.
• W2148911877 hasAuthorship W2148911877A5082579643 @default.
• W2148911877 hasAuthorship W2148911877A5083202398 @default.
• W2148911877 hasBestOaLocation W21489118772 @default.
• W2148911877 hasConcept C126322002 @default.
• W2148911877 hasConcept C143998085 @default.
• W2148911877 hasConcept C151730666 @default.
• W2148911877 hasConcept C167734588 @default.
• W2148911877 hasConcept C2777025900 @default.
• W2148911877 hasConcept C2778715236 @default.

• next